We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Ventas (VTR) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Analysts on Wall Street project that Ventas (VTR - Free Report) will announce quarterly earnings of $0.75 per share in its forthcoming report, representing an increase of 1.4% year over year. Revenues are projected to reach $1.16 billion, increasing 8.1% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Ventas metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenues- Resident fees and services' reaching $784.47 million. The estimate suggests a change of +11.3% year over year.
Analysts forecast 'Revenues- Income from loans and investments' to reach $2.62 million. The estimate suggests a change of -80.7% year over year.
Based on the collective assessment of analysts, 'Revenues- Rental income- Outpatient medical & research portfolio' should arrive at $221.52 million. The estimate points to a change of +9.1% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Depreciation and amortization' of $363.52 million. Compared to the current estimate, the company reported $282.12 million in the same quarter of the previous year.
Shares of Ventas have demonstrated returns of +4.2% over the past month compared to the Zacks S&P 500 composite's -2.5% change. With a Zacks Rank #4 (Sell), VTR is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Ventas (VTR) Q1 Earnings, Beyond Revenue and EPS
Analysts on Wall Street project that Ventas (VTR - Free Report) will announce quarterly earnings of $0.75 per share in its forthcoming report, representing an increase of 1.4% year over year. Revenues are projected to reach $1.16 billion, increasing 8.1% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Ventas metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenues- Resident fees and services' reaching $784.47 million. The estimate suggests a change of +11.3% year over year.
Analysts forecast 'Revenues- Income from loans and investments' to reach $2.62 million. The estimate suggests a change of -80.7% year over year.
Based on the collective assessment of analysts, 'Revenues- Rental income- Outpatient medical & research portfolio' should arrive at $221.52 million. The estimate points to a change of +9.1% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Depreciation and amortization' of $363.52 million. Compared to the current estimate, the company reported $282.12 million in the same quarter of the previous year.
View all Key Company Metrics for Ventas here>>>
Shares of Ventas have demonstrated returns of +4.2% over the past month compared to the Zacks S&P 500 composite's -2.5% change. With a Zacks Rank #4 (Sell), VTR is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>